3 2 2 5 3

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊





更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

已发表论文

基于配体的靶向治疗:肝细胞癌治疗的一种新策略

 

Authors Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC

Received 24 June 2016

Accepted for publication 19 September 2016

Published 31 October 2016 Volume 2016:11 Pages 5645—5669

DOI https://doi.org/10.2147/IJN.S115727

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Alexander Kharlamov

Peer reviewer comments 3

Editor who approved publication: Dr Linlin Sun

Abstract: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with high morbidity and mortality worldwide. Chemotherapy is recommended to patients with intermediate or advanced stage cancer. However, the conventional chemotherapy yields low desired response rates due to multidrug resistance, fast clearance rate, nonspecific delivery, severe side effects, low drug concentration in cancer cells, and so on. Nanoparticle-mediated targeted drug delivery system can surmount the aforementioned obstacles through enhanced permeability and retention effect and active targeting as a novel approach of therapeutics for HCC in recent years. The active targeting is triggered by ligands on the delivery system, which recognize with and internalize into hepatoma cells with high specificity and efficiency. This review focuses on the latest targeted delivery systems for HCC and summarizes the ligands that can enhance the capacity of active targeting, to provide some insight into future research in nanomedicine for HCC.
Keywords: targeted therapy, hepatocellular carcinoma, ligand, drug delivery system, nanoparticle